Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

被引：0
|
作者：
Avram Goldberg
Thomas Geppert
Elena Schiopu
Tracy Frech
Vivien Hsu
Robert W Simms
Stanford L Peng
Yihong Yao
Nairouz Elgeioushi
Linda Chang
Bing Wang
Stephen Yoo
机构：
[1] Hofstra North Shore-LIJ School of Medicine,North Shore LIJ Health Systems and Division of Rheumatology
[2] Metroplex Clinical Research Center,undefined
[3] LLC,undefined
[4] University of Michigan,undefined
[5] University of Utah,undefined
[6] RWJ Medical School Clinical Research Center,undefined
[7] Boston University School Of Medicine,undefined
[8] Benaroya Research Institute at Virginia Mason Medical Center,undefined
[9] MedImmune,undefined
[10] MedImmune,undefined
来源：
Arthritis Research & Therapy | / 16卷
关键词：
Human Papilloma Virus; Chronic Myelogenous Leukemia; Evaluable Population; Positive Baseline; Minimum Anticipate Biological Effect Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] RESULTS OF A RANDOMIZED PLACEBO CONTROLLED PHASE IA STUDY OF AGS-009, A HUMANIZED ANTI-INTERFERON-α MONOCLONAL ANTIBODY IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Tcherepanova, I.
    Curtis, M.
    Sale, M.
    Miesowicz, F.
    Nicolette, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 536 - 537
  • [22] A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.
    Shapira, Roni
    Weber, Jeffrey S.
    Geva, Ravit
    Sznol, Mario
    Kluger, Harriet M.
    Wong, Deborah J. L.
    Liang, Bertrand C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
    Xiaoxue Zhu
    Yanhua Ding
    Qian Wang
    Guiyu Yang
    Liang Zhou
    Qingyu Wang
    Investigational New Drugs, 2023, 41 : 473 - 482
  • [24] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
    Zhu, Xiaoxue
    Ding, Yanhua
    Wang, Qian
    Yang, Guiyu
    Zhou, Liang
    Wang, Qingyu
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 473 - 482
  • [25] A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab
    McKenzie, Andrew
    Roberts, Anthony
    Malandkar, Sourabh
    Feuersenger, Henrike
    Panousis, Con
    Pawaskar, Dipti
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 626 - 637
  • [26] An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
    Gordon, Michael S.
    Robert, Francisco
    Matei, Daniela
    Mendelson, David S.
    Goldman, Jonathan W.
    Chiorean, E. Gabriela
    Strother, Robert M.
    Seon, Ben K.
    Figg, William D.
    Peer, Cody J.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Rosen, Lee S.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5918 - 5926
  • [27] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [28] First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis
    Gottlieb, Alice B.
    Krueger, James G.
    Lundblad, Mia Sandberg
    Gothberg, Marie
    Skolnick, Brett E.
    PLOS ONE, 2015, 10 (08):
  • [29] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Okada, Masato
    Ishii, Tomonori
    Nakajima, Hiroshi
    Kawai, Shinichi
    Nagashima, Takao
    Hayashi, Nobuya
    Wang, Liangwei
    Tummala, Raj
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 101 - 108
12345